Stock Details
ABBV is AbbVie Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 140.88$. Average daily volumn in 3 months 5.55M. Market cap 251.05B



Stock symbol : ABBV. Exchange : NYSE. Currency : USD
Lastest price : 141.99$. Total volume : 6.24M. Market state PREPRE
Click reload if you want to check the lastest price on market!!!

AbbVie Inc. (ABBV)
Last Price
141.99$
Change
3.67
Volume
6.24M

Previous Close138.32
Open139.21
Day Range137.76-142.72
Bid0.00 x 900
Ask0.00 x 800
Volume6.24M
Average Volume5.55M
Market Cap251.05B
Beta0.69
52 Week Range106.86-175.91
Trailing P/E20.08
Foward P/E12.01
Dividend (Yield %)4.20%
Ex-Dividend Date2022-10-13



Financial Details


According to AbbVie Inc.'s financial reports the company's revenue in 2021 were 56.2B an increase( +24.44%) over the years 2020 revenue that were of 45.8B. In 2021 the company's total earnings were 11.54B while total earnings in 2020 were 4.62B( +175%).


Loading ...



Organization

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behรงet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCL... EXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Market Cap:
251.05B
Revenue:
56.2B
Total Assets:
146.53B
Total Cash:
9.75B


News about "AbbVie Inc."

here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock-image

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

Source from : Zacks.com on MSN - 1 days ago

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...See details»


abbvie-inc-nyseabbv-is-a-favorite-amongst-institutional-investors-who-own-70-image

AbbVie Inc. (NYSE:ABBV) is a favorite amongst institutional investors who own 70%

Source from : Yahoo - 7 days ago

To get a sense of who is truly in control of AbbVie Inc. (NYSE:ABBV), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are ...See details»


abbvie-incs-nyseabbv-business-is-trailing-the-market-but-its-shares-arent-image

AbbVie Inc.'s (NYSE:ABBV) Business Is Trailing The Market But Its Shares Aren't

Source from : YAHOO!Finance - 11 days ago

With a price-to-earnings (or "P/E") ratio of 20.1x AbbVie Inc. ( NYSE:ABBV ) may be sending bearish signals at ...See details»


culbertson-a-n-co-inc-has-1250-million-position-in-abbvie-inc-nyseabbv-image

Culbertson A N & Co Inc Has $12.50 Million Position in AbbVie Inc. (NYSE:ABBV)

Source from : Defense World - 2 days ago

Culbertson A N & Co Inc lessened its stake in AbbVie Inc. (NYSE:ABBV โ€“ Get Rating) by 0.7% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange ...See details»


bogart-wealth-llc-grows-holdings-in-abbvie-inc-nyseabbv-image

Bogart Wealth LLC Grows Holdings in AbbVie Inc. (NYSE:ABBV)

Source from : Defense World - 1 days ago

Bogart Wealth LLC grew its stake in AbbVie Inc. (NYSE:ABBV โ€“ Get Rating) by 19.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange ...See details»


When Abbvie Inc (ABBV) Moves Investors should Listen

Source from : MarketWatch - 2 days ago

This report optimizes trading in Abbvie Inc (NASDAQ: ABBV) with integrated risk controls. The trading plans were valid at the time this was published, but the support and resistance levels for ABBV ...See details»


AbbVie Inc. (ABBV): Donโ€™t ignore this Blaring Warning Signal

Source from : investchronicle - 7 days ago

For the readers interested in the stock health of AbbVie Inc. (ABBV). It is currently valued at $143.83. When the transactions were called off in the previous session, Stock hit the highs of $142.80, ...See details»


AbbVie a Top Ranked SAFE Dividend Stock With 4.0% Yield (ABBV)

Source from : Nasdaq - 22 days ago

AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.0% yield, as well as a ...See details»


Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?

Source from : Nasdaq - 25 days ago

AbbVie (ABBV) is one of the stocks most watched ... of the author and do not necessarily reflect those of Nasdaq, Inc. Zacks is the leading investment research firm focusing on stock research ...See details»


abbvie-incs-nyseabbv-institutional-investors-lost-62-last-week-but-have-benefitted-from-longer-term-gains-image

AbbVie Inc.'s (NYSE:ABBV) institutional investors lost 6.2% last week but have benefitted from longer-term gains

Source from : Yahoo Finance - 3 days ago

If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its ...See details»


Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

Source from : YAHOO!Finance - 14 days ago

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.See details»


AbbVie, Tesla, Financial Select Sector SPDR, iShares 20 Plus Year Treasury Bond And This Airline Are CNBC's Final Trades

Source from : Benzinga.com - 27 days ago

On CNBCโ€™s โ€œHalftime Report Final Trades,โ€ Bryn Talkington of Requisite Capital Management said that AbbVie Inc ABBV has โ€œcome down from 175.โ€ โ€œItโ€™s at 134, itโ€™s got a 4% yield ...See details»


moderna-inc-stock-rises-tuesday-outperforms-market-image

Moderna Inc. stock rises Tuesday, outperforms market

Source from : MarketWatch on MSN - 17 hours ago

Shares of Moderna Inc. advanced 3.87% to $125.67 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 3.34% to 11,176.41 ...See details»


One AbbVie Inc. (NYSE:ABBV) insider reduced their stake by 86% in the previous year

Source from : Yahoo - 15 days ago

Insiders were net sellers of AbbVie Inc.'s (NYSE:ABBV ) stock during the past year. That is, insiders sold more stock than they bought. While insider transactions are not the most important thing ...See details»